tirzepatide health canada approval in π£ BIG NEWS IN OBESITY MEDICINE! π¨π¦ Canada has officially Weight-loss drug approved to treat
Description
Slowed gastric motility means food moves more slowly through the entire digestive tract
But that energy comes at the cost of increased heart rate, blood pressure, insomnia, and potential dependency
G lucagon-like peptide-1 (GLP-1) receptor agonists are known to exert beneficial effects on inflammation, insulin resistance, glycemic control, body weight, and lipid metabolism
However, evidence for this combination remains anecdotal rather than clinically validated
$249/mo)
